|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leiomyomatosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphangioleiomyomatosis | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Leiomyoma | |||||
| Lymphangiomyoma | |||||
| Lymphatic Diseases | |||||
| Lymphatic Vessel Tumors | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Connective and Soft Tissue | |||||
| Neoplasms, Muscle Tissue | |||||
| 4 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||